Palmitoylethanolamide prevents metabolic alterations and restores leptin sensitivity in ovariectomized rats

Endocrinology

Volumn 155, Issue 4, 2014, Pages 1291-1301

  Raso, G Mattace ^a   Santoro, A ^a   Russo, R ^a   Simeoli, R ^a   Paciello, O ^a   Di Carlo, C ^a   Diano, S ^b   Calignano, A ^a   Meli, Rosaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA; LEPTIN; NEUROPEPTIDE; PALMIDROL; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FAT MASS; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; HYPERPHAGIA; HYPOTHALAMUS; NONHUMAN; OBESITY; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TREATMENT DURATION; WEIGHT GAIN;

ADENOSINE TRIPHOSPHATE; ADIPOKINES; AMIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; CELL LINE, TUMOR; CYTOKINES; EATING; ENDOCANNABINOIDS; ETHANOL; ETHANOLAMINES; FATTY ACIDS; FEEDING BEHAVIOR; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; LEPTIN; OBESITY; OVARIECTOMY; PALMITIC ACIDS; PHOSPHORYLATION; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; WEIGHT GAIN;

EID: 84897873973     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1823     Document Type: Article

References (59)

1. Bachur NR, Masek K, Melmon KL, Undenfriend S. Fatty acid amides of ethanolamine in mammalian tissues. J Biol Chem. 1965;240:1019-1024.
2. Lo Verme J, Fu J, Astarita G, et al. The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005;67:15-19. (Pubitemid 40069962)
3. LoVerme J, Russo R, La Rana G, et al. Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-α. J Pharmacol Exp Ther. 2006;319:1051-1061.
4. D'Agostino G, La Rana G, Russo R, et al. Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-α agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther. 2007;322:1137-1143. (Pubitemid 47295805)
5. D'Agostino G, La Rana G, Russo R, et al. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-κB nuclear signalling in dorsal root ganglia. Eur J Pharmacol. 2009;613:54-59.
6. Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR α in energy metabolism and vascular homeostasis. J Clin Invest. 2006;116:571-580. (Pubitemid 43326861)
7. Cullingford TE, Bhakoo K, Peuchen S, Dolphin CT, Patel R, Clark JB. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor α, β, and γ and the retinoid X receptor α, β, and γ in rat central nervous system. J Neurochem. 1998;70:1366-1375. (Pubitemid 28136948)
8. Varga T, Czimmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta. 2011;1812:1007-1022.
9. Hansen HS, Diep TA. N-acylethanolamines, anandamide and food intake. Biochem Pharmacol. 2009;78:553-560.
10. Rodríguez de Fonseca F, Navarro M, Gómez R, et al. An anorexic lipid mediator regulated by feeding. Nature. 2001;414:209-212. (Pubitemid 33051235)
11. Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature. 2003;425:90-93. (Pubitemid 37101723)
12. Lee SS, Pineau T, Drago J, et al. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol. 1995;15:3012-3022.
13. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM. Physiological response to long term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci USA. 1997;94:8878-8883. (Pubitemid 27335133)
14. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature. 2002;415:339-343. (Pubitemid 34087557)
15. Muoio DM, Lynis Dohm G. Peripheral metabolic actions of leptin. Best Pract Res Clin Endocrinol Metab. 2002;16:653-666.
16. Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428:569-574. (Pubitemid 38480541)
17. Andersson U, Filipsson K, Abbott CR, et al. AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem. 2004;279:12005-12008. (Pubitemid 38445761)
18. Mountjoy PD, Bailey SJ, Rutter GA. Inhibition by glucose or leptin of hypothalamic neurons expressing neuropeptide Y requires changes in AMP-activated protein kinase activity. Diabetologia. 2007;50:168-177. (Pubitemid 46035865)
19. Meli R, Pacilio M, Raso GM, et al. Estrogen and raloxifene modulate leptin and its receptor in hypothalamus and adipose tissue from ovariectomized rats. Endocrinology. 2004;145:3115-3121. (Pubitemid 38829980)
20. Abeles Ed, Cordeiro LM, Martins Ade S, et al. Estrogen therapy attenuates adiposity markers in spontaneously hypertensive rats. Metabolism. 2012;61:1100-1107.
21. Qiu J, Bosch MA, Tobias SC, et al. G-protein-coupled estrogen receptor is involved in hypothalamic control of energy homeostasis. J Neurosci. 2006;26:5649-5655. (Pubitemid 44315256)
22. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85-97.
23. Romeo GR, Lee J, Shoelson SE. Metabolic syndrome, insulin resistance, and roles of inflammation-mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol. 2012;32:1771-1776.
24. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444:860-867. (Pubitemid 46024993)
25. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796-1808. (Pubitemid 38063703)
26. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175-184. (Pubitemid 46048464)
27. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793-1801. (Pubitemid 44033299)
28. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91. (Pubitemid 23036092)
29. Mohamed-Ali V, Flower L, Sethi J, et al. β-Adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab. 2001;86:5864-5869. (Pubitemid 33152636)
30. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest. 2006;116:33-35. (Pubitemid 43121788)
31. Mattace Raso G, Simeoli R, Russo R, et al. N-palmitoylethanolamide protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress. Pharmacol Res. 2013;76:67-76.
32. Ilagan J, Bhutani V, Archer P, Lin PK, Jen KL. Estimation of body composition changes during weight cycling by bioelectrical impedance analysis in rats. J Appl Physiol. 1993;74:2092-2098. (Pubitemid 23157024)
33. Laird PW, Zijderveld A, Linders K, Rudnicki MA, Jaenisch R, Berns. A simplified mammalian DNA isolation procedure. Nucleic Acids Res. 1991;19:4293.
34. Bjørbaek C, Elmquist JK, Frantz JD, Shoelson SE, Flier JS. Identification of SOCS-3 as a potential mediator of central leptin resistance. Mol Cell. 1998;1:619-625. (Pubitemid 128374698)
35. Cheng A, Uetani N, Simoncic PD, et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev Cell. 2002;2:497-503. (Pubitemid 34436577)
36. Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell. 2002;2:489-495. (Pubitemid 34436576)
37. Bjørbaek C, El-Haschimi K, Frantz JD, Flier JS. The role of SOCS-3 in leptin signaling and leptin resistance. J Biol Chem. 1999;274:30059-30065.
38. Bjorbak C, Lavery HJ, Bates SH, et al. SOCS3 mediates feedback inhibition of the leptin receptor via Tyr985. J Biol Chem. 2000;275:40649-40657. (Pubitemid 32064706)
39. Münzberg H, Myers MG Jr. Molecular and anatomical determinants of central leptin resistance. Nat Neurosci. 2005;8:566-570. (Pubitemid 40594195)
40. Starr R, Willson TA, Viney EM, et al. Afamily of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917-921.
41. Wang J, Campbell IL. Cytokine signaling in the brain: putting a SOCS in it? J Neurosci Res. 2002;67:423-427. (Pubitemid 34117111)
42. Wang R, Swick AG. Identification and characterization of a leptin-responsive neuroblastoma cell line. Biochem Biophys Res Commun. 2009;379:835-839.
43. Jang EH, Park CS, Lee SK, Pie JE, Kang JH. Excessive nitric oxide attenuates leptin-mediated signal transducer and activator of transcription 3 activation. Life Sci. 2007;80:609-617.
44. Monteiro R, Azevedo I. Chronic inflammation in obesity and metabolic syndrome. Mediators Inflamm. 2010;2010; ID289645.
45. Kim JY, van de Wall E, Laplante M, et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest. 2007;117:2621-2637. (Pubitemid 47494363)
46. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med. 2002;8:731-737. (Pubitemid 34778727)
47. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science. 1998;281:1683-1686. (Pubitemid 28435586)
48. Glass CK, Olefsky JM. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012;15:635-645.
49. Gustafson B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb. 2010;17:332-341.
50. Nishimura S, Manabe I, Nagasaki M, et al. Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels. Diabetes. 2007;56:1517-1526. (Pubitemid 46842598)
51. Nishimura S, Manabe I, Nagasaki M, et al. In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. J Clin Invest. 2008;118:710-721. (Pubitemid 351206559)
52. Yang Z, Kahn BB, Shi H, Xue BZ. Macrophage α1 AMP-activated protein kinase (α1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J Biol Chem. 2010;285:19051-10059.
53. Sag D, Carling D, Stout RD, Suttles J. Adenosine 5′-monophosphate- activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J Immunol. 2008;181:8633-8641.
54. Lihn AS, Pedersen SB, Lund S, Richelsen B. The anti-diabetic AMPK activator AICAR reduces IL-6 and IL-8 in human adipose tissue and skeletal muscle cells. Mol Cell Endocrinol. 2008;292:36-41.
55. Unger RH. The hyperleptinemia of obesity-regulator of caloric surpluses. Cell. 2004;117:145-146.
56. Clegg DJ, Riedy CA, Smith KA, Benoit SC, Woods SC. Differential sensitivity to central leptin and insulin in male and female rats. Diabetes. 2003;52:682-687. (Pubitemid 36323575)
57. Clegg DJ, Benoit S, Barrera J, Woods SC. Estrogen mediates body fat distribution and brain sensitivity to adiposity signals. Diabetes. 2003;52(suppl 1):A24 (Abstract).
58. Hulka BS. Epidemiologic analysis of breast and gynecologic cancers. Prog Clin Biol Res. 1997;396:17-29.
59. Lindenfeld J, Ghali JK, Krause-Steinrauf HJ, et al. Hormone replacement therapy is associated with improved survival in woman with advanced heart failure. J Am Coll Cardiol. 2003;42:1238-1245. (Pubitemid 37188349)